OXYGENTA PHARMACEUTICAL
|
The Current P/E Ratio of OXYGENTA PHARMACEUTICAL is -13.47.
| Share Price | ₹62.3 | Nov 17,2025 |
| Market Cap | ₹230.6 Cr | |
| Earnings-TTM | ₹-17.1 Cr | TTM-Standalone Results |
| Price/Earnings | -13.47x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of OXYGENTA PHARMACEUTICAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹230.6 Cr] as on Nov 17,2025
(/) Earnings [ ₹-17.1 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ -13.47x ]
Thus, for OXYGENTA PHARMACEUTICAL , the investors are currently willing to pay -13.47 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of OXYGENTA PHARMACEUTICAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of OXYGENTA PHARMACEUTICAL over the last five years.
Historical PE (Price/Earnings) ratio chart of OXYGENTA PHARMACEUTICAL
PE Ratio Performance Analysis for OXYGENTA PHARMACEUTICAL
- OXYGENTA PHARMACEUTICAL 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 0.00x.
- OXYGENTA PHARMACEUTICAL 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, OXYGENTA PHARMACEUTICAL 's p/e ratio peaked in Mar2025 at 0x.
- OXYGENTA PHARMACEUTICAL 's p/e ratio hit its five-year low in Mar2025 of 0x.
How does OXYGENTA PHARMACEUTICAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| OXYGENTA PHARMACEUTICAL | -17.12 | -13.47 | 230.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.23 | 423,171.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 69.69 | 173,172.0 |
| CIPLA LTD | 5,453.86 | 22.75 | 124,094.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 60.36 | 129,176.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.15 | 103,869.0 |
| MANKIND PHARMA LTD | 1,767.06 | 52.44 | 92,658.1 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.90 | 94,012.4 |
| LUPIN LTD | 4,347.53 | 21.56 | 93,713.9 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.84 | 71,856.8 |
| ABBOTT INDIA LTD | 1,508.95 | 41.69 | 62,904.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs OXYGENTA PHARMACEUTICAL 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -13.47x |
| Max industry PE | 69.69x |
| Median industry PE | 22.75x |
| Average industry PE | 32.10x |
You may also like the below Video Courses